Gastroenterology Research and Practice / 2019 / Article / Tab 2

Research Article

Increased Serum Soluble Urokinase Plasminogen Activator Receptor Predicts Short-Term Outcome in Patients with Hepatitis B-Related Acute-on-Chronic Liver Failure

Table 2

Baseline demographic, clinical, and laboratory characteristics of HB-ACLF survivors and nonsurvivors in the validated set.

TotalSurvivorsNonsurvivors

Number16710364
Age (yr)43 (19-69)40 (19-69)44.5 (24-66)0.155
Sex, male (, %)140 (83.8)86 (83.5)54 (84.3)0.881
HBeAg positive (n, %)74 (44.3)46 (44.7)28 (43.8)0.908
HBV-DNA (lg copies/ml)5.93 (1.15-9.82)5.82 (1.70-9.82)6.10 (1.15-9.43)0.376
Serum bilirubin (mg/dl)20.19 (6.49-73.01)17.85 (6.49-73.01)22.69 (10.08-54.42)0.001
Serum albumin (g/l)30 (17-45)31 (19-45)29 (17-42)0.167
ALT (U/ml)549 (21-4747)537 (21-4747)578 (29-3742)0.603
AST (U/ml)335 (28-4202)320 (49-4202)365 (28-2598)0.799
INR2.22 (1.30-14.58)2.07 (1.30-4.19)2.95 (1.55-14.58)≤0.001
Baseline sCr (mg/dl)67 (33-378)66 (38-221)68 (33-378)0.653
Leukocyte count (109/l)7.46 (2.39-22.34)6.87 (2.87-15.6)8.29 (2.39-22.34)0.016
Platelet count (109/l)108 (30-246)108 (30-211)111.5 (33-246)0.824
MELD score24 (16-50)23 (16-32)27.5 (16-50)≤0.001
CLIF-C OF10 (6-16)9 (6-12)11 (8-16)≤0.001
CRP (ng/ml)10.9 (0.65-138.00)10.5 (2.3-138)12.08 (0.65-137)0.979
PCT (ng/ml)0.63 (0.16-34.99)0.64 (0.24-2.35)0.70 (0.16-34.99)0.184
SuPAR (ng/ml)10.75 (1.18-121.76)7.85 (1.18-65.38)19.8 (1.36-121.76)≤0.001
Complications (, %)
 Infection108 (64.7)57 (55.3)51 (79.7)0.001
 Gastrointestinal bleeding18 (10.8)7 (6.8)11 (17.2)0.035
Hepatic encephalopathy63 (37.7)14 (13.6)49 (76.6)≤0.001
 HRS13 (7.8)2 (1.9)11 (17.2)0.001

: number; yr: year; sCr: serum creatinine; MELD: model for end-stage liver disease; CLIF-C OF: chronic liver failure consortium organ failure; CRP: C-reactive protein; PCT: procalcitonin; HRS: hepatorenal syndrome.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.